<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2025-06-05</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0000275053</issuerCik>
        <issuerName>NATURES SUNSHINE PRODUCTS INC</issuerName>
        <issuerTradingSymbol>NATR</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0002071437</rptOwnerCik>
            <rptOwnerName>Fosun Pharma USA Inc.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>104 CARNEGIE CENTER DRIVE</rptOwnerStreet1>
            <rptOwnerStreet2>SUITE 204</rptOwnerStreet2>
            <rptOwnerCity>PRINCETON</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>08540</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isTenPercentOwner>true</isTenPercentOwner>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>2854607</value>
                    <footnoteId id="F1"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. transferred these shares to its wholly-owned subsidiary, Fosun Pharma USA Inc.  Following the transfer, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and Fosun Pharma USA Inc. intend to jointly file Section 16 reports with respect to these shares.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>Fosun Pharma USA Inc. By: /s/ Yuqing Wang, Chief Financial Officer</signatureName>
        <signatureDate>2025-06-09</signatureDate>
    </ownerSignature>
</ownershipDocument>
